$10.91
+0.04
(+0.37%)▲
2.8%
Downside
Day's Volatility :3.64%
Upside
0.87%
20.62%
Downside
52 Weeks Volatility :52.73%
Upside
40.45%
Period | Alphatec Holdings Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -12.62% | 6.5% | 0.0% |
6 Months | -33.11% | 7.1% | 0.0% |
1 Year | -37.2% | 9.8% | 0.0% |
3 Years | -22.96% | 14.2% | -20.2% |
Market Capitalization | 1.5B |
Book Value | $0.26 |
Earnings Per Share (EPS) | -1.47 |
PEG Ratio | 0.0 |
Wall Street Target Price | 22.21 |
Profit Margin | -37.45% |
Operating Margin TTM | -27.62% |
Return On Assets TTM | -13.9% |
Return On Equity TTM | -1451.77% |
Revenue TTM | 511.6M |
Revenue Per Share TTM | 3.97 |
Quarterly Revenue Growth YOY | 26.900000000000002% |
Gross Profit TTM | 233.1M |
EBITDA | -87.2M |
Diluted Eps TTM | -1.47 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.06 |
EPS Estimate Next Year | -0.69 |
EPS Estimate Current Quarter | -0.31 |
EPS Estimate Next Quarter | -0.29 |
What analysts predicted
Upside of 103.57%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 91.7M | ↓ 9.87% |
Net Income | -29.0M | ↑ 1163.08% |
Net Profit Margin | -31.6% | ↓ 29.35% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 113.4M | ↑ 23.7% |
Net Income | -56.9M | ↑ 96.38% |
Net Profit Margin | -50.17% | ↓ 18.57% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 144.9M | ↑ 27.71% |
Net Income | -79.0M | ↑ 38.82% |
Net Profit Margin | -54.53% | ↓ 4.36% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 243.2M | ↑ 67.89% |
Net Income | -144.3M | ↑ 82.71% |
Net Profit Margin | -59.34% | ↓ 4.81% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 350.9M | ↑ 44.26% |
Net Income | -152.1M | ↑ 5.42% |
Net Profit Margin | -43.36% | ↑ 15.98% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 482.3M | ↑ 37.45% |
Net Income | -186.6M | ↑ 22.67% |
Net Profit Margin | -38.7% | ↑ 4.66% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 105.9M | ↑ 17.93% |
Net Income | -35.0M | ↓ 5.44% |
Net Profit Margin | -33.02% | ↑ 8.16% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 109.1M | ↑ 2.99% |
Net Income | -43.5M | ↑ 24.42% |
Net Profit Margin | -39.89% | ↓ 6.87% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 116.9M | ↑ 7.16% |
Net Income | -51.4M | ↑ 18.03% |
Net Profit Margin | -43.94% | ↓ 4.05% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 118.3M | ↑ 1.15% |
Net Income | -42.7M | ↓ 16.98% |
Net Profit Margin | -36.07% | ↑ 7.87% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 138.0M | ↑ 16.66% |
Net Income | -49.1M | ↑ 15.06% |
Net Profit Margin | -35.57% | ↑ 0.5% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 138.5M | ↑ 0.37% |
Net Income | -48.5M | ↓ 1.19% |
Net Profit Margin | -35.02% | ↑ 0.55% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 129.5M | ↑ 52.94% |
Total Liabilities | 111.9M | ↑ 0.53% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 169.9M | ↑ 31.26% |
Total Liabilities | 126.3M | ↑ 12.88% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 261.2M | ↑ 53.71% |
Total Liabilities | 131.3M | ↑ 3.98% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 572.1M | ↑ 118.99% |
Total Liabilities | 492.6M | ↑ 275.07% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 513.4M | ↓ 10.26% |
Total Liabilities | 550.1M | ↑ 11.66% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 805.2M | ↑ 56.85% |
Total Liabilities | 703.5M | ↑ 27.89% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 513.4M | ↓ 0.56% |
Total Liabilities | 550.1M | ↑ 2.09% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 569.7M | ↑ 10.97% |
Total Liabilities | 628.1M | ↑ 14.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 628.2M | ↑ 10.28% |
Total Liabilities | 656.4M | ↑ 4.51% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 670.2M | ↑ 6.68% |
Total Liabilities | 714.4M | ↑ 8.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 805.2M | ↑ 20.14% |
Total Liabilities | 703.5M | ↓ 1.52% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 774.6M | ↓ 3.8% |
Total Liabilities | 713.4M | ↑ 1.41% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.6M | ↑ 193.37% |
Investing Cash Flow | -21.7M | ↑ 233.63% |
Financing Cash Flow | 53.9M | ↑ 202.37% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.1M | ↑ 29.34% |
Investing Cash Flow | -13.0M | ↓ 39.86% |
Financing Cash Flow | 64.2M | ↑ 19.11% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -46.4M | ↑ 40.13% |
Investing Cash Flow | -23.9M | ↑ 83.08% |
Financing Cash Flow | 130.8M | ↑ 103.84% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -73.4M | ↑ 58.22% |
Investing Cash Flow | -157.8M | ↑ 561.23% |
Financing Cash Flow | 312.0M | ↑ 138.45% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -75.1M | ↑ 2.33% |
Investing Cash Flow | -58.3M | ↓ 63.06% |
Financing Cash Flow | 31.2M | ↓ 89.99% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.4M | ↓ 42.8% |
Investing Cash Flow | -14.8M | ↓ 5.07% |
Financing Cash Flow | 1.0M | ↓ 96.56% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 9.6M | ↓ 213.9% |
Investing Cash Flow | -16.8M | ↑ 13.35% |
Financing Cash Flow | 67.1M | ↑ 6524.88% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -17.9M | ↓ 286.73% |
Investing Cash Flow | -75.6M | ↑ 349.35% |
Financing Cash Flow | 77.9M | ↑ 16.1% |
Sell
Neutral
Buy
Alphatec Holdings Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Alphatec Holdings Inc | 4.42% | -33.11% | -37.2% | -22.96% | 110.25% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Alphatec Holdings Inc | NA | NA | 0.0 | -1.06 | -14.52 | -0.14 | NA | 0.26 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Alphatec Holdings Inc | Buy | $1.5B | 110.25% | NA | -37.45% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Alphatec Holdings Inc
Revenue is up for the last 9 quarters, 70.93M → 138.47M (in $), with an average increase of 7.8% per quarter
Netprofit is up for the last 2 quarters, -49.07M → -48.49M (in $), with an average increase of 1.2% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 78.9%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 91.9%
BlackRock Inc
Vanguard Group Inc
First Light Asset Management, LLC
Millennium Management LLC
American Century Companies Inc
JPMorgan Chase & Co
as a medical technology company, we improve lives by providing innovative spine surgery solutions through our relentless pursuit of superior outcomes. we are dedicated to the design, development, launch and the delivery of spinal fusion products. we seek to accomplish this by working with spine surgeons to design and develop products and systems that address the entire spinal fusion procedure in the most effective and efficient way possible. our product designs and platforms provide innovation through a focus on simplifying procedures for the surgeon with the ultimate objective of superior outcomes. alphatec spine is seeking growth through innovation and continually developing technologies that will have a greater positive impact on patient care and outcomes. please visit our website for more information: www.alphatecspine.com
Organization | Alphatec Holdings Inc |
Employees | 839 |
CEO | Mr. Patrick S. Miles |
Industry | Health Technology |
A Spac I Acquisition Corp
$10.91
+0.37%
Keyarch Acquisition Corp
$10.91
+0.37%
Connexa Sports Technologies Inc
$10.91
+0.37%
Us Value Etf
$10.91
+0.37%
First Wave Biopharma Inc
$10.91
+0.37%
Global X Msci Next Emerging
$10.91
+0.37%
Fat Projects Acquisition Corp
$10.91
+0.37%
Capital Link Global Fintech
$10.91
+0.37%
Applied Uv Inc
$10.91
+0.37%